Showing posts with label Effectiveness. Show all posts
Showing posts with label Effectiveness. Show all posts

Friday, September 27, 2013

0 The Effectiveness of Modern Antihistamines for Treatment of Allergic Rhinitis

Abstract




 ORIGINAL ARTICLE
The Effectiveness of Modern Antihistamines for Treatment of Allergic Rhinitis – An IPD Meta-Analysis of 140,853 Patients
doi:10.2332/allergolint.12-OA-0486



Ralph Mösges, Volker König and Juliane Köberlein [About this authors]
ABSTRACT
Background: Allergic rhinitis represents a worldwide health problem. The prevalence is increasing. The aim of this study was to analyse the correlation between the severity of allergic rhinitis and an adequate treatment dose of modern oral antihistamines.
Methods: From a comprehensive databank containing data from ten different open-label prospective observational studies including raw data of 140,853 patients with allergic rhinitis, symptomatology variables were analysed and scored to study the effects of treatment with four antihistamines (Desloratadine, Ebastine, Fexofenadine, Levocetirizine) alone or in combination with intranasal corticosteroids. The patient data were collected in 23,606 study centres from Germany, mostly medical specialist and some primary care physicians in private practice. The analyses were performed via individual patient data meta-analysis techniques.
Results: Finally 92,900 patient data from nine of ten studies could be analysed. One study with data of 47,953 patients was excluded due to incomplete treatment documentation. Both monotherapy analysis subgroups (Total Symptom Score and Total Nasal Symptom Score) were significantly better than those of their combinations with intranasal steroids. Monotherapy with levocetirizine was determined to be significantly more effective in lowering the Total Symptom Score (p < 0.001) and the Total Nasal Symptom Score (p < 0.05) than the other antihistamines. In the next stage, a greater positive effect of levocetirizine was demonstrated in relation to the severity of the clinical symptoms of allergic rhinitis (Total Nasal Symptom Score in cases with severe symptomatology [effect size = -0.09]).
Conclusions: Levocetirizine asserted itself as the only antihistamine compared with the others as significant in this analysis. The study authors recommend monotherapy with the new-generation antihistamine levocetirizine, especially in severe cases of allergic rhinitis.

KEY WORDS:
allergic rhinitis, Desloratadine, Ebastine, Fexofenadine, Levocetirizine, treatment
ABBREVIATIONS:
TNSS, Total Nasal Symptom Score; TOSS,Total Ocular Symptom Score; TSS, Total Symptom Score; IPD, Individual Patient Data.

Received: 30 July 2012.
Accepted: 28 November 2012.
Allergology International : In Press








Saturday, September 14, 2013

0 Effectiveness of influenza vaccination in working-age adults with diabetes: a population-based cohort study

Thorax 68:658-663 doi:10.1136/thoraxjnl-2012-203109Epidemiology


  • Original article



Effectiveness of influenza vaccination in working-age adults with diabetes: a population-based cohort study


Open Access









  1. Jeffrey A Johnson1


+Author Affiliations




  1. 1Department of Public Health Sciences, University of Alberta, Edmonton, Canada




  2. 2Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada




  3. 3Department of Community Health Sciences, University of Manitoba, Winnipeg, Canada





  1. Correspondence toDr Jeffrey A Johnson, 2-040G Li Ka Shing Center for Health Research Innovation, 8602 112 Street, Department of Public Health Sciences, University of Alberta, Edmonton, Canada, AB T6G 2E1; jeff.johnson@ualberta.ca



  • Received 7 December 2012

  • Revised 7 February 2013

  • Accepted 2 March 2013

  • Published Online First 27 March 2013




Abstract



Background Guidelines recommend influenza vaccinations in all diabetic adults, but there is limited evidence to support vaccinating working-age adults (65>



Methods We identified all adults with diabetes, along with a sample of age-matched and sex-matched comparison subjects without diabetes, from 2000 to 2008, using administrative data from Manitoba, Canada. With multivariable Poisson regression, we estimated vaccine effectiveness (VE) on influenza-like illnesses (ILIs), pneumonia and influenza (PI) hospitalisations and all-cause (ALL) hospitalisations during periods of known circulating influenza. Analyses were replicated outside of influenza season to rule out residual confounding.



Results We included 543 367 person-years of follow-up, during which 223 920 ILI, 5422 PI and 94 988 ALL occurred. The majority (58%) of adults with diabetes were working age. In this group, influenza vaccination was associated with relative reductions in PI (43%, 95% CI 28% to 54%) and ALL (28%, 95% CI 24% to 32%) but not ILI (−1%, 95% CI −3% to 1%). VE was similar in elderly adults for ALL (33–34%) and PI (45–55%), although not ILI (12–13%). However, similar estimates of effectiveness were also observed for all three groups during non-influenza control periods.



Conclusions Working-age adults with diabetes experience similar benefits from vaccination as elderly adults, supporting current diabetes-specific recommendations. However, these benefits were also manifest outside of influenza season, suggesting residual bias. Vaccination recommendations in all high-risk adults would benefit from randomised trial evidence.

This Article







  1. Supplementary Data


  2. All Versions of this Article:

    1. thoraxjnl-2012-203109v1

    2. 68/7/658 most recent









This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/3.0/ andhttp://creativecommons.org/licenses/by-nc/3.0/legalcode